Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

44.81USD
22 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$44.81
Open
--
Day's High
--
Day's Low
--
Volume
6
Avg. Vol
8,834,823
52-wk High
$45.84
52-wk Low
$36.76

Latest Key Developments (Source: Significant Developments)

FTC approves final order settling charges for Abbott's deal with St. Jude Medical
Thursday, 23 Feb 2017 01:18pm EST 

U.S. FTC: Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive .Abbott is required to notify FTC if it intends to buy lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics.  Full Article

Abbott Laboratories commences exchange offers, consent solicitations for St. Jude Medical notes
Tuesday, 21 Feb 2017 08:55am EST 

Abbott Laboratories :Abbott laboratories - Abbott commences exchange offers and consent solicitations for St. Jude Medical LLC notes.  Full Article

ABBOTT SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE
Friday, 17 Feb 2017 11:25am EST 

Abbott :SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE.  Full Article

European Commission clears Abbott acquisition of Alere
Wednesday, 25 Jan 2017 11:00am EST 

Alere Inc : European Commission clears Abbott acquisition of Alere .Alere inc - "We remain highly confident that merger will close according to terms of agreement" with Abbott.  Full Article

Abbott CEO says is optimistic about the Trump administration: Conf Call
Wednesday, 25 Jan 2017 10:15am EST 

Abbott Laboratories : Abbott says expect challenging conditions in China's nutrition market to continue in the near term: Conf Call . Abbott expects relatively flat sales growth in nutrition for Q1: Conf Call . Abbott CEO says St. Jude's fourth quarter CRM unit sales continue to struggle, but we expect that to change shortly: Conf Call . Abbott expects China nutrition sales growth to improve through 2017 : Conf Call . Abbott CEO says "in general I am optimistic" about the new administration : Conf Call . Abbott CEO says "I don't really expect changes to ACA to directly affect us": Conf Call . Abbott CEO says St. Jude acquisition helps deepen exposure into developed markets : Conf Call . Abbott CEO says the few changes that come with Trump administration in the near term, and likely impact Abbott favourably: Conf Call . Abbott CEO not focusing too much on M&A and share repurchases in the near term, focus on paying down debt: Conf Call . Abbott CEO says performance of freestyle device ouside the U.S. has been good, and Abbott is upbeat about securing U.S. approval: Conf Call . Abbott CEO says revenue growth rate for St. Jude was about 2.5 percent for the fourth quarter : Conf Call . Abbott says negative FX impact in Q1 is relatively more than other quarters : Conf Call Further company coverage: [ABT.N] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Abbott reports Q4 sales of $5.3 billion
Wednesday, 25 Jan 2017 07:30am EST 

Abbott Laboratories : Abbott reports fourth-quarter 2016 results . Q4 GAAP earnings per share $0.51 from continuing operations . Q4 earnings per share view $0.65 -- Thomson Reuters I/B/E/S . Sees Q1 adjusted earnings per share $0.42 to $0.44 from continuing operations excluding items . Sees FY 2017 adjusted earnings per share $2.40 to $2.50 from continuing operations excluding items . Sees Q1 2017 GAAP earnings per share $0.19 to $0.21 from continuing operations . Sees FY 2017 GAAP earnings per share $0.92 to $1.02 from continuing operations . Q4 sales $5.3 billion versus I/B/E/S view $5.38 billion . Q4 adjusted earnings per share $0.65 from continuing operations excluding items . Abbott Laboratories qtrly total pediatric sales $977 million versus $1,034 million . Abbott Laboratories qtrly total nutrition sales $1,733 million versus. $1,800 million last year . Abbott Laboratories qtrly total diagnostics sales $1,256 million versus $1,220 million last year . Abbott Laboratories qtrly total vascular sales $721 million, up 0.6 percent on an operational basis . Q4 earnings per share view $0.65, revenue view $5.38 billion -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $2.46 -- Thomson Reuters I/B/E/S . Q1 earnings per share view $0.50 -- Thomson Reuters I/B/E/S.  Full Article

St. Jude to deploy cyber-security updates for Merlin remote monitoring system
Monday, 9 Jan 2017 12:08pm EST 

St Jude Medical Inc : St. Jude Medical announces cybersecurity updates . Will immediately deploy latest release of cyber security updates for its Merlin remote monitoring system . Is not aware of any cyber security incidents related to a St. Jude Medical device . Also not aware that any specific St. Jude Medical device or system in clinical use has been purposely targeted .Company also plans to implement additional updates in 2017.  Full Article

China conditionally approves Abbott Laboratories' acquisition of St Jude
Friday, 30 Dec 2016 04:18am EST 

China Commerce Ministry says:Conditionally approves Abbott Laboratories' acquisition of St Jude Medical Inc Full Article

Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia
Wednesday, 12 Oct 2016 07:49am EDT 

Abbott Laboratories : Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML . Celgene - companion diagnostic technology to be utilized with Enasidenib, AG-120 development programs for relapsed/refractory acute myeloid leukemia .Celgene-Agreements with abbott to develop,commercialize companion diagnostic tests on Abbott's M2000 realtime system to identify IDH mutations in AML.  Full Article

U.S. FDA provides recommendations regarding St. Jude Medical's devices
Tuesday, 11 Oct 2016 10:09am EDT 

U.S. FDA - : U.S. FDA-Providing information, recommendations regarding St. Jude Medical's advisory on ICD and CRT-D batteries that may fail earlier than expected . u.s. Fda-Fda , st. Jude medical alerting patients, patient-caregivers, and physicians to respond immediately to elective replacement indicator alerts . U.S. FDA says St. Jude medical has initiated recall, correction of affected devices; at this time, 349,852 affected devices remain actively implanted worldwide .U.S. FDA says at this time, no information indicating that issue affects devices manufactured after May 2015.  Full Article

More From Around the Web

Higher heart risk seen with Abbott dissolving stent after two years: study

WASHINGTON Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.